person · Reporting owner

KLEMP WALTER V

Disclosed activity across 3 companies

Tapewire entity: 26374
SEC CIK: 0000938419

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Autonomix Medical, Inc.AMIX · Entity 8309	Director	September 03, 2026	September 08, 2026
Moleculin Biotech, Inc.MBRX · Entity 7886	Director · CEO and President	August 03, 2026	August 05, 2026
Soliton, Inc.SOLY · Entity 132212	Director · Executive Chairman	December 16, 2021	December 17, 2021

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Autonomix Medical, Inc.

Report date September 03, 2026 · Filed September 08, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	20,118	Reported balance After 2026-09-03 transaction · row 1 1 source row Row 1 · 2026-09-03 · Grant · Acquired 13,000 · Balance 20,118 F1: Represents restricted stock award vesting one-year from the date of issuance of September 3, 2026.

Filing footnotes · ownership attribution and instrument terms

F1: Represents restricted stock award vesting one-year from the date of issuance of September 3, 2026.

Moleculin Biotech, Inc.

Report date August 03, 2026 · Filed August 05, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	564,340	Reported balance After 2026-08-03 transaction · row 1 1 source row Row 1 · 2026-08-03 · Purchase · Acquired 533,333 · Balance 564,340 F1: On August 3, 2026, the reporting person acquired 533,333 shares of common stock and Series I warrants to purchase 1,599,999 shares of common stock at a combined purchase price of $0.75 per one share of common stock and three accompanying warrants in a public offering.
Series I WarrantsSEC Table II · derivative / convertible security · Expires 2031-08-03	Direct	1,926,335	Reported balance After 2026-08-03 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-08-03 · Grant · Acquired 1,599,999 · Balance 1,926,335 F1: On August 3, 2026, the reporting person acquired 533,333 shares of common stock and Series I warrants to purchase 1,599,999 shares of common stock at a combined purchase price of $0.75 per one share of common stock and three accompanying warrants in a public offering.

Filing footnotes · ownership attribution and instrument terms

F1: On August 3, 2026, the reporting person acquired 533,333 shares of common stock and Series I warrants to purchase 1,599,999 shares of common stock at a combined purchase price of $0.75 per one share of common stock and three accompanying warrants in a public offering.

Soliton, Inc.

Report date December 16, 2021 · Filed December 17, 2021

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2021-12-16 transaction · row 1 1 source row Row 1 · 2021-12-16 · Disposition to issuer · Disposed 425,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of May 8, 2021 (the "Merger Agreement"), by and among Soliton, Inc. (the "Company"), AbbVie Inc. ("AbbVie") and Scout Merger Sub, Inc., a wholly owned subsidiary of AbbVie ("Merger Sub"), at the effective time of the merger of Merger Sub with and into the Company (the "Merger"), these shares of Company common stock were converted into the right to receive $22.60 in cash (the "Merger Consideration"), without interest.
Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.75 · Expires 2028-06-07	Direct	Reported balance After 2021-12-16 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2021-12-16 · Disposition to issuer · Disposed 725,000 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding and unexercised option, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the Merger Consideration minus the exercise price that would be due in cash upon exercise of such option.
Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.75 · Expires 2029-02-04	Direct	Reported balance After 2021-12-16 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2021-12-16 · Disposition to issuer · Disposed 84,500 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding and unexercised option, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the Merger Consideration minus the exercise price that would be due in cash upon exercise of such option.
Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.62 · Expires 2029-06-27	Direct	Reported balance After 2021-12-16 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2021-12-16 · Disposition to issuer · Disposed 35,150 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding and unexercised option, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the Merger Consideration minus the exercise price that would be due in cash upon exercise of such option.
Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.71 · Expires 2030-02-04	Direct	Reported balance After 2021-12-16 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2021-12-16 · Disposition to issuer · Disposed 89,300 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding and unexercised option, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the Merger Consideration minus the exercise price that would be due in cash upon exercise of such option.
Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.74 · Expires 2031-01-21	Direct	Reported balance After 2021-12-16 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2021-12-16 · Disposition to issuer · Disposed 113,000 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding and unexercised option, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the Merger Consideration minus the exercise price that would be due in cash upon exercise of such option.
Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.75 · Expires 2023-10-19	Direct	Reported balance After 2021-12-16 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2021-12-16 · Disposition to issuer · Disposed 11,512 · Balance 0 F3: Pursuant to the Merger Agreement, at the effective time of the Merger, each outstanding and unexercised warrant, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the excess of (i) the number of shares of common stock subject to the warrant, multiplied by the Merger Consideration over (ii) the number of shares of common stock subject to the warrant, multiplied by the per share exercise price of such warrant.
Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.75 · Expires 2023-10-30	Direct	Reported balance After 2021-12-16 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2021-12-16 · Disposition to issuer · Disposed 8,634 · Balance 0 F3: Pursuant to the Merger Agreement, at the effective time of the Merger, each outstanding and unexercised warrant, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the excess of (i) the number of shares of common stock subject to the warrant, multiplied by the Merger Consideration over (ii) the number of shares of common stock subject to the warrant, multiplied by the per share exercise price of such warrant.
Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.75 · Expires 2023-11-15	Direct	Reported balance After 2021-12-16 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2021-12-16 · Disposition to issuer · Disposed 7,771 · Balance 0 F3: Pursuant to the Merger Agreement, at the effective time of the Merger, each outstanding and unexercised warrant, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the excess of (i) the number of shares of common stock subject to the warrant, multiplied by the Merger Consideration over (ii) the number of shares of common stock subject to the warrant, multiplied by the per share exercise price of such warrant.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger, dated as of May 8, 2021 (the "Merger Agreement"), by and among Soliton, Inc. (the "Company"), AbbVie Inc. ("AbbVie") and Scout Merger Sub, Inc., a wholly owned subsidiary of AbbVie ("Merger Sub"), at the effective time of the merger of Merger Sub with and into the Company (the "Merger"), these shares of Company common stock were converted into the right to receive $22.60 in cash (the "Merger Consideration"), without interest.

F2: Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding and unexercised option, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the Merger Consideration minus the exercise price that would be due in cash upon exercise of such option.

F3: Pursuant to the Merger Agreement, at the effective time of the Merger, each outstanding and unexercised warrant, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the excess of (i) the number of shares of common stock subject to the warrant, multiplied by the Merger Consideration over (ii) the number of shares of common stock subject to the warrant, multiplied by the per share exercise price of such warrant.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 22, 2023 Filed Jun 26, 2023 22:20 UTC	Moleculin Biotech, Inc. MBRX · Entity 7886	GrantStock option (right to buy) · Derivative	400,000	Not disclosed Strike: $0.60	Not disclosed	Disclosure SEC source: 0001437749-23-018529 · rdgdoc.xml · derivative · entry 1 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,416,691 Underlying: Common Stock · 400,000 shares Expires 2033-06-22 F2 · price: Issued in connection with the reporting person's employment with the Company.Issued in connection with the reporting person's employment with the Company. F1 · derivative.exercise_date: The stock option set forth in this table vests in four equal annual installments beginning on the first anniversary of the Transaction Date, subject to the grantee's continued service to the Company on each vesting date. Read SEC document
June 20, 2023 Filed Jun 22, 2023 23:00 UTC	Moleculin Biotech, Inc. MBRX · Entity 7886	Exercise / conversionRestricted Stock Units · Derivative	56,250	$0.00	$0.00	Disclosure SEC source: 0001437749-23-018140 · rdgdoc.xml · derivative · entry 3 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,016,691 Underlying: Common Stock · 56,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On June 20, 2022, the reporting person was granted 225,000 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F3 · derivative.expiration_date: On June 20, 2022, the reporting person was granted 225,000 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document
June 20, 2023 Filed Jun 22, 2023 23:00 UTC	Moleculin Biotech, Inc. MBRX · Entity 7886	Tax withholdingCommon Stock	13,697	$0.57	$7,807.29	Disclosure SEC source: 0001437749-23-018140 · rdgdoc.xml · nonDerivative · entry 2 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 471,355 F2 · shares: Shares withheld for payment of taxes upon vesting of restricted stock unit awards. Read SEC document
June 20, 2023 Filed Jun 22, 2023 23:00 UTC	Moleculin Biotech, Inc. MBRX · Entity 7886	Exercise / conversionCommon Stock	56,250	Not disclosed	Not disclosed	Disclosure SEC source: 0001437749-23-018140 · rdgdoc.xml · nonDerivative · entry 1 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 485,052 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document
June 16, 2023 Filed Jun 20, 2023 22:00 UTC	Moleculin Biotech, Inc. MBRX · Entity 7886	Exercise / conversionRestricted Stock Units · Derivative	25,000	$0.00	$0.00	Disclosure SEC source: 0001437749-23-017884 · rdgdoc.xml · derivative · entry 3 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,072,941 Underlying: Common Stock · 25,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On June 16, 2021, the reporting person was granted 100,000 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F3 · derivative.expiration_date: On June 16, 2021, the reporting person was granted 100,000 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document
June 16, 2023 Filed Jun 20, 2023 22:00 UTC	Moleculin Biotech, Inc. MBRX · Entity 7886	Tax withholdingCommon Stock	6,088	$0.57	$3,470.16	Disclosure SEC source: 0001437749-23-017884 · rdgdoc.xml · nonDerivative · entry 2 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 428,802 F2 · shares: Shares withheld for payment of taxes upon vesting of restricted stock unit awards. Read SEC document
June 16, 2023 Filed Jun 20, 2023 22:00 UTC	Moleculin Biotech, Inc. MBRX · Entity 7886	Exercise / conversionCommon Stock	25,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001437749-23-017884 · rdgdoc.xml · nonDerivative · entry 1 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 434,890 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document
November 25, 2022 Filed Nov 28, 2022 23:00 UTC	Moleculin Biotech, Inc. MBRX · Entity 7886	PurchaseCommon Stock	45,000	$1.28	$57,631.50	Disclosure SEC source: 0001437749-22-028116 · rdgdoc.xml · nonDerivative · entry 1 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 409,890 F1 · price: This transaction was executed in multiple trades at prices ranging from $1.25 to $1.30. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
November 21, 2022 Filed Nov 23, 2022 13:30 UTC	Moleculin Biotech, Inc. MBRX · Entity 7886	PurchaseCommon Stock	22,500	$1.15	$25,866.00	Disclosure SEC source: 0001437749-22-027949 · rdgdoc.xml · nonDerivative · entry 1 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 364,890 F1 · price: This transaction was executed in multiple trades at prices ranging from $1.12 to $1.17. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
November 17, 2022 Filed Nov 19, 2022 01:34 UTC	Moleculin Biotech, Inc. MBRX · Entity 7886	PurchaseCommon Stock	24,742	$1.02	$25,256.63	Disclosure SEC source: 0001437749-22-027792 · rdgdoc.xml · nonDerivative · entry 2 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 342,390 F2 · price: This transaction was executed in multiple trades at prices ranging from $0.995 to $1.04. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
November 16, 2022 Filed Nov 19, 2022 01:34 UTC	Moleculin Biotech, Inc. MBRX · Entity 7886	PurchaseCommon Stock	85,213	$0.97	$82,614.00	Disclosure SEC source: 0001437749-22-027792 · rdgdoc.xml · nonDerivative · entry 1 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 317,648 F1 · price: This transaction was executed in multiple trades at prices ranging from $0.935 to $1.02. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
July 11, 2022 Filed Jul 13, 2022 21:00 UTC	Moleculin Biotech, Inc. MBRX · Entity 7886	Exercise / conversionRestricted Stock Units · Derivative	13,205	$0.00	$0.00	Disclosure SEC source: 0001437749-22-017075 · rdgdoc.xml · derivative · entry 3 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,369,941 Underlying: Common Stock · 13,204 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On July 11, 2019, the reporting person was granted 52,818 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F3 · derivative.expiration_date: On July 11, 2019, the reporting person was granted 52,818 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document
July 11, 2022 Filed Jul 13, 2022 21:00 UTC	Moleculin Biotech, Inc. MBRX · Entity 7886	Tax withholdingCommon Stock	3,215	$1.68	$5,401.20	Disclosure SEC source: 0001437749-22-017075 · rdgdoc.xml · nonDerivative · entry 2 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,435 F2 · shares: Shares withheld for payment of taxes upon vesting of restricted stock unit awards. Read SEC document
July 11, 2022 Filed Jul 13, 2022 21:00 UTC	Moleculin Biotech, Inc. MBRX · Entity 7886	Exercise / conversionCommon Stock	13,204	Not disclosed	Not disclosed	Disclosure SEC source: 0001437749-22-017075 · rdgdoc.xml · nonDerivative · entry 1 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,650 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document
July 11, 2022 Filed Jul 16, 2022 00:03 UTC Amendment	Moleculin Biotech, Inc. MBRX · Entity 7886	Exercise / conversionRestricted Stock Units · Derivative	13,205	$0.00	$0.00	Disclosure SEC source: 0001437749-22-017219 · rdgdoc.xml · derivative · entry 3 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,097,941 Underlying: Common Stock · 13,204 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On July 11, 2019, the reporting person was granted 52,818 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F3 · derivative.expiration_date: On July 11, 2019, the reporting person was granted 52,818 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document
July 11, 2022 Filed Jul 16, 2022 00:03 UTC Amendment	Moleculin Biotech, Inc. MBRX · Entity 7886	Tax withholdingCommon Stock	3,215	$1.68	$5,401.20	Disclosure SEC source: 0001437749-22-017219 · rdgdoc.xml · nonDerivative · entry 2 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,435 F2 · shares: Shares withheld for payment of taxes upon vesting of restricted stock unit awards. Read SEC document
July 11, 2022 Filed Jul 16, 2022 00:03 UTC Amendment	Moleculin Biotech, Inc. MBRX · Entity 7886	Exercise / conversionCommon Stock	13,204	Not disclosed	Not disclosed	Disclosure SEC source: 0001437749-22-017219 · rdgdoc.xml · nonDerivative · entry 1 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,650 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document
July 02, 2022 Filed Jul 6, 2022 22:02 UTC	Moleculin Biotech, Inc. MBRX · Entity 7886	Exercise / conversionRestricted Stock Units · Derivative	14,717	$0.00	$0.00	Disclosure SEC source: 0001437749-22-016754 · rdgdoc.xml · derivative · entry 3 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,383,145 Underlying: Common Stock · 14,717 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On July 2, 2020, the reporting person was granted 58,869 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F3 · derivative.expiration_date: On July 2, 2020, the reporting person was granted 58,869 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document
July 02, 2022 Filed Jul 6, 2022 22:02 UTC	Moleculin Biotech, Inc. MBRX · Entity 7886	Tax withholdingCommon Stock	3,584	$1.47	$5,268.48	Disclosure SEC source: 0001437749-22-016754 · rdgdoc.xml · nonDerivative · entry 2 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,446 F2 · shares: Shares withheld for payment of taxes upon vesting of restricted stock unit awards. Read SEC document
July 02, 2022 Filed Jul 6, 2022 22:02 UTC	Moleculin Biotech, Inc. MBRX · Entity 7886	Exercise / conversionCommon Stock	14,717	Not disclosed	Not disclosed	Disclosure SEC source: 0001437749-22-016754 · rdgdoc.xml · nonDerivative · entry 1 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,030 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document
July 02, 2022 Filed Jul 16, 2022 00:04 UTC Amendment	Moleculin Biotech, Inc. MBRX · Entity 7886	Exercise / conversionRestricted Stock Units · Derivative	14,717	$0.00	$0.00	Disclosure SEC source: 0001437749-22-017220 · rdgdoc.xml · derivative · entry 3 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,111,145 Underlying: Common Stock · 14,717 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On July 2, 2020, the reporting person was granted 58,869 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F3 · derivative.expiration_date: On July 2, 2020, the reporting person was granted 58,869 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document
July 02, 2022 Filed Jul 16, 2022 00:04 UTC Amendment	Moleculin Biotech, Inc. MBRX · Entity 7886	Tax withholdingCommon Stock	3,584	$1.47	$5,268.48	Disclosure SEC source: 0001437749-22-017220 · rdgdoc.xml · nonDerivative · entry 2 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,446 F2 · shares: Shares withheld for payment of taxes upon vesting of restricted stock unit awards. Read SEC document
July 02, 2022 Filed Jul 16, 2022 00:04 UTC Amendment	Moleculin Biotech, Inc. MBRX · Entity 7886	Exercise / conversionCommon Stock	14,717	Not disclosed	Not disclosed	Disclosure SEC source: 0001437749-22-017220 · rdgdoc.xml · nonDerivative · entry 1 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,030 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document
June 20, 2022 Filed Jun 22, 2022 23:04 UTC	Moleculin Biotech, Inc. MBRX · Entity 7886	GrantRestricted Stock Units · Derivative	362,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001437749-22-015663 · rdgdoc.xml · derivative · entry 2 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,397,862 Underlying: Common stock · 362,000 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one shares of Company common stock. F2 · price: Issued in connection with the reporting person's employment with the Company. F4 · derivative.exercise_date: The restricted stock units set forth in this table vests in four equal annual installments beginning on the first anniversary of the Transaction Date, subject to the grantee's continued service to the Company on each vesting date. F4 · derivative.expiration_date: The restricted stock units set forth in this table vests in four equal annual installments beginning on the first anniversary of the Transaction Date, subject to the grantee's continued service to the Company on each vesting date. Read SEC document
June 20, 2022 Filed Jun 22, 2022 23:04 UTC	Moleculin Biotech, Inc. MBRX · Entity 7886	GrantStock option (right to buy) · Derivative	360,000	Not disclosed Strike: $1.49	Not disclosed	Disclosure SEC source: 0001437749-22-015663 · rdgdoc.xml · derivative · entry 1 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,035,862 Underlying: Common stock · 360,000 shares Expires 2032-06-20 F2 · price: Issued in connection with the reporting person's employment with the Company. F1 · derivative.exercise_date: The stock option set forth in this table vests in four equal annual installments beginning on the first anniversary of the Transaction Date, subject to the grantee's continued service to the Company on each vesting date. Read SEC document
June 20, 2022 Filed Jul 16, 2022 00:03 UTC Amendment	Moleculin Biotech, Inc. MBRX · Entity 7886	GrantRestricted Stock Units · Derivative	225,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001437749-22-017218 · rdgdoc.xml · derivative · entry 2 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,125,862 Underlying: Common stock · 225,000 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one shares of Company common stock. F2 · price: Issued in connection with the reporting person's employment with the Company. F4 · derivative.exercise_date: The restricted stock units set forth in this table vests in four equal annual installments beginning on the first anniversary of the Transaction Date, subject to the grantee's continued service to the Company on each vesting date. F4 · derivative.expiration_date: The restricted stock units set forth in this table vests in four equal annual installments beginning on the first anniversary of the Transaction Date, subject to the grantee's continued service to the Company on each vesting date. Read SEC document
June 20, 2022 Filed Jul 16, 2022 00:03 UTC Amendment	Moleculin Biotech, Inc. MBRX · Entity 7886	GrantStock option (right to buy) · Derivative	225,000	Not disclosed Strike: $1.49	Not disclosed	Disclosure SEC source: 0001437749-22-017218 · rdgdoc.xml · derivative · entry 1 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 900,862 Underlying: Common stock · 225,000 shares Expires 2032-06-20 F2 · price: Issued in connection with the reporting person's employment with the Company. F1 · derivative.exercise_date: The stock option set forth in this table vests in four equal annual installments beginning on the first anniversary of the Transaction Date, subject to the grantee's continued service to the Company on each vesting date. Read SEC document
June 16, 2022 Filed Jun 22, 2022 00:08 UTC	Moleculin Biotech, Inc. MBRX · Entity 7886	Exercise / conversionRestricted Stock Units · Derivative	25,000	$0.00	$0.00	Disclosure SEC source: 0001437749-22-015536 · rdgdoc.xml · derivative · entry 3 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 675,862 Underlying: Common Stock · 25,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On June 16, 2021, the reporting person was granted 100,000 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F3 · derivative.expiration_date: On June 16, 2021, the reporting person was granted 100,000 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document
June 16, 2022 Filed Jun 22, 2022 00:08 UTC	Moleculin Biotech, Inc. MBRX · Entity 7886	Tax withholdingCommon Stock	6,088	$1.33	$8,097.04	Disclosure SEC source: 0001437749-22-015536 · rdgdoc.xml · nonDerivative · entry 2 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,313 F2 · shares: Shares withheld for payment of taxes upon vesting of restricted stock unit awards. Read SEC document
June 16, 2022 Filed Jun 22, 2022 00:08 UTC	Moleculin Biotech, Inc. MBRX · Entity 7886	Exercise / conversionCommon Stock	25,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001437749-22-015536 · rdgdoc.xml · nonDerivative · entry 1 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,401 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document
December 16, 2021 Filed Dec 17, 2021 22:09 UTC	Soliton, Inc. SOLY · Entity 132212	Disposition to issuerWarrant (right to buy) · Derivative	7,771	Not disclosed Strike: $1.75	Not disclosed	Disclosure SEC source: 0001548187-21-000079 · wf-form4_163977896166120.xml · derivative · entry 9 KLEMP WALTER V · CIK 0000938419 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,771 shares Expires 2023-11-15 F3 · price: Pursuant to the Merger Agreement, at the effective time of the Merger, each outstanding and unexercised warrant, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the excess of (i) the number of shares of common stock subject to the warrant, multiplied by the Merger Consideration over (ii) the number of shares of common stock subject to the warrant, multiplied by the per share exercise price of such warrant. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the effective time of the Merger, each outstanding and unexercised warrant, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the excess of (i) the number of shares of common stock subject to the warrant, multiplied by the Merger Consideration over (ii) the number of shares of common stock subject to the warrant, multiplied by the per share exercise price of such warrant. Read SEC document
December 16, 2021 Filed Dec 17, 2021 22:09 UTC	Soliton, Inc. SOLY · Entity 132212	Disposition to issuerWarrant (right to buy) · Derivative	8,634	Not disclosed Strike: $1.75	Not disclosed	Disclosure SEC source: 0001548187-21-000079 · wf-form4_163977896166120.xml · derivative · entry 8 KLEMP WALTER V · CIK 0000938419 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,634 shares Expires 2023-10-30 F3 · price: Pursuant to the Merger Agreement, at the effective time of the Merger, each outstanding and unexercised warrant, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the excess of (i) the number of shares of common stock subject to the warrant, multiplied by the Merger Consideration over (ii) the number of shares of common stock subject to the warrant, multiplied by the per share exercise price of such warrant. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the effective time of the Merger, each outstanding and unexercised warrant, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the excess of (i) the number of shares of common stock subject to the warrant, multiplied by the Merger Consideration over (ii) the number of shares of common stock subject to the warrant, multiplied by the per share exercise price of such warrant. Read SEC document
December 16, 2021 Filed Dec 17, 2021 22:09 UTC	Soliton, Inc. SOLY · Entity 132212	Disposition to issuerWarrant (right to buy) · Derivative	11,512	Not disclosed Strike: $1.75	Not disclosed	Disclosure SEC source: 0001548187-21-000079 · wf-form4_163977896166120.xml · derivative · entry 7 KLEMP WALTER V · CIK 0000938419 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,512 shares Expires 2023-10-19 F3 · price: Pursuant to the Merger Agreement, at the effective time of the Merger, each outstanding and unexercised warrant, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the excess of (i) the number of shares of common stock subject to the warrant, multiplied by the Merger Consideration over (ii) the number of shares of common stock subject to the warrant, multiplied by the per share exercise price of such warrant. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the effective time of the Merger, each outstanding and unexercised warrant, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the excess of (i) the number of shares of common stock subject to the warrant, multiplied by the Merger Consideration over (ii) the number of shares of common stock subject to the warrant, multiplied by the per share exercise price of such warrant. Read SEC document
December 16, 2021 Filed Dec 17, 2021 22:09 UTC	Soliton, Inc. SOLY · Entity 132212	Disposition to issuerStock option (right to buy) · Derivative	113,000	Not disclosed Strike: $9.74	Not disclosed	Disclosure SEC source: 0001548187-21-000079 · wf-form4_163977896166120.xml · derivative · entry 6 KLEMP WALTER V · CIK 0000938419 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 113,000 shares Expires 2031-01-21 F2 · price: Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding and unexercised option, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the Merger Consideration minus the exercise price that would be due in cash upon exercise of such option. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding and unexercised option, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the Merger Consideration minus the exercise price that would be due in cash upon exercise of such option. Read SEC document
December 16, 2021 Filed Dec 17, 2021 22:09 UTC	Soliton, Inc. SOLY · Entity 132212	Disposition to issuerStock option (right to buy) · Derivative	89,300	Not disclosed Strike: $11.71	Not disclosed	Disclosure SEC source: 0001548187-21-000079 · wf-form4_163977896166120.xml · derivative · entry 5 KLEMP WALTER V · CIK 0000938419 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 89,300 shares Expires 2030-02-04 F2 · price: Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding and unexercised option, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the Merger Consideration minus the exercise price that would be due in cash upon exercise of such option. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding and unexercised option, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the Merger Consideration minus the exercise price that would be due in cash upon exercise of such option. Read SEC document
December 16, 2021 Filed Dec 17, 2021 22:09 UTC	Soliton, Inc. SOLY · Entity 132212	Disposition to issuerStock option (right to buy) · Derivative	35,150	Not disclosed Strike: $14.62	Not disclosed	Disclosure SEC source: 0001548187-21-000079 · wf-form4_163977896166120.xml · derivative · entry 4 KLEMP WALTER V · CIK 0000938419 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,150 shares Expires 2029-06-27 F2 · price: Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding and unexercised option, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the Merger Consideration minus the exercise price that would be due in cash upon exercise of such option. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding and unexercised option, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the Merger Consideration minus the exercise price that would be due in cash upon exercise of such option. Read SEC document
December 16, 2021 Filed Dec 17, 2021 22:09 UTC	Soliton, Inc. SOLY · Entity 132212	Disposition to issuerStock option (right to buy) · Derivative	84,500	Not disclosed Strike: $1.75	Not disclosed	Disclosure SEC source: 0001548187-21-000079 · wf-form4_163977896166120.xml · derivative · entry 3 KLEMP WALTER V · CIK 0000938419 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 84,500 shares Expires 2029-02-04 F2 · price: Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding and unexercised option, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the Merger Consideration minus the exercise price that would be due in cash upon exercise of such option. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding and unexercised option, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the Merger Consideration minus the exercise price that would be due in cash upon exercise of such option. Read SEC document
December 16, 2021 Filed Dec 17, 2021 22:09 UTC	Soliton, Inc. SOLY · Entity 132212	Disposition to issuerStock option (right to buy) · Derivative	725,000	Not disclosed Strike: $1.75	Not disclosed	Disclosure SEC source: 0001548187-21-000079 · wf-form4_163977896166120.xml · derivative · entry 2 KLEMP WALTER V · CIK 0000938419 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 725,000 shares Expires 2028-06-07 F2 · price: Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding and unexercised option, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the Merger Consideration minus the exercise price that would be due in cash upon exercise of such option. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding and unexercised option, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the Merger Consideration minus the exercise price that would be due in cash upon exercise of such option. Read SEC document
December 16, 2021 Filed Dec 17, 2021 22:09 UTC	Soliton, Inc. SOLY · Entity 132212	Disposition to issuerCommon Stock	425,000	$22.60	$9,605,000.00	Disclosure SEC source: 0001548187-21-000079 · wf-form4_163977896166120.xml · nonDerivative · entry 1 KLEMP WALTER V · CIK 0000938419 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of May 8, 2021 (the "Merger Agreement"), by and among Soliton, Inc. (the "Company"), AbbVie Inc. ("AbbVie") and Scout Merger Sub, Inc., a wholly owned subsidiary of AbbVie ("Merger Sub"), at the effective time of the merger of Merger Sub with and into the Company (the "Merger"), these shares of Company common stock were converted into the right to receive $22.60 in cash (the "Merger Consideration"), without interest. F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of May 8, 2021 (the "Merger Agreement"), by and among Soliton, Inc. (the "Company"), AbbVie Inc. ("AbbVie") and Scout Merger Sub, Inc., a wholly owned subsidiary of AbbVie ("Merger Sub"), at the effective time of the merger of Merger Sub with and into the Company (the "Merger"), these shares of Company common stock were converted into the right to receive $22.60 in cash (the "Merger Consideration"), without interest. Read SEC document
July 11, 2021 Filed Jul 12, 2021 21:57 UTC	Moleculin Biotech, Inc. MBRX · Entity 7886	Exercise / conversionRestricted Stock Units · Derivative	13,205	$0.00	$0.00	Disclosure SEC source: 0001437749-21-016790 · rdgdoc.xml · derivative · entry 3 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 700,862 Underlying: Common Stock · 13,205 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On July 11, 2019, the reporting person was granted 52,818 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F3 · derivative.expiration_date: On July 11, 2019, the reporting person was granted 52,818 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document
July 11, 2021 Filed Jul 12, 2021 21:57 UTC	Moleculin Biotech, Inc. MBRX · Entity 7886	Tax withholdingCommon Stock	3,215	$3.56	$11,445.40	Disclosure SEC source: 0001437749-21-016790 · rdgdoc.xml · nonDerivative · entry 2 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,401 F2 · shares: Shares withheld for payment of taxes upon vesting of restricted stock unit awards. Read SEC document
July 11, 2021 Filed Jul 12, 2021 21:57 UTC	Moleculin Biotech, Inc. MBRX · Entity 7886	Exercise / conversionCommon Stock	13,205	Not disclosed	Not disclosed	Disclosure SEC source: 0001437749-21-016790 · rdgdoc.xml · nonDerivative · entry 1 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,616 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document
July 02, 2021 Filed Jul 6, 2021 11:30 UTC	Moleculin Biotech, Inc. MBRX · Entity 7886	Exercise / conversionRestricted Stock Units · Derivative	14,718	$0.00	$0.00	Disclosure SEC source: 0001437749-21-016394 · rdgdoc.xml · derivative · entry 3 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 717,651 Underlying: Common Stock · 14,718 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On July 2, 2020, the reporting person was granted 58,869 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F3 · derivative.expiration_date: On July 2, 2020, the reporting person was granted 58,869 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document
July 02, 2021 Filed Jul 6, 2021 11:30 UTC	Moleculin Biotech, Inc. MBRX · Entity 7886	Tax withholdingCommon Stock	3,584	$3.56	$12,759.04	Disclosure SEC source: 0001437749-21-016394 · rdgdoc.xml · nonDerivative · entry 2 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,411 F2 · shares: Shares withheld for payment of taxes upon vesting of restricted stock unit awards. Read SEC document
July 02, 2021 Filed Jul 6, 2021 11:30 UTC	Moleculin Biotech, Inc. MBRX · Entity 7886	Exercise / conversionCommon Stock	14,718	Not disclosed	Not disclosed	Disclosure SEC source: 0001437749-21-016394 · rdgdoc.xml · nonDerivative · entry 1 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,995 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document
June 16, 2021 Filed Jun 21, 2021 20:20 UTC	Moleculin Biotech, Inc. MBRX · Entity 7886	GrantRestricted Stock Units · Derivative	100,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001437749-21-015274 · rdgdoc.xml · derivative · entry 2 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 728,785 Underlying: Common Stock · 100,000 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Company common stock. F2 · price: Issued in connection with the reporting person's employment with the Company. F4 · derivative.exercise_date: The restricted stock units set forth in this table vest in four equal annual installments beginning on the first anniversary of the Transaction Date, subject to the grantee's continued service to the Company on each vesting date. F4 · derivative.expiration_date: The restricted stock units set forth in this table vest in four equal annual installments beginning on the first anniversary of the Transaction Date, subject to the grantee's continued service to the Company on each vesting date. Read SEC document
June 16, 2021 Filed Jun 21, 2021 20:20 UTC	Moleculin Biotech, Inc. MBRX · Entity 7886	GrantStock option (right to buy) · Derivative	223,635	Not disclosed Strike: $3.73	Not disclosed	Disclosure SEC source: 0001437749-21-015274 · rdgdoc.xml · derivative · entry 1 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 628,785 Underlying: Common Stock · 223,635 shares Expires 2031-06-16 F2 · price: Issued in connection with the reporting person's employment with the Company. F1 · derivative.exercise_date: The options set forth in this table vest in four equal annual installments, beginning on the first anniversary of the Transaction Date, subject to the grantee's continued service to the Company on each vesting date. Read SEC document
April 15, 2021 Filed Apr 16, 2021 21:22 UTC	Soliton, Inc. SOLY · Entity 132212	GrantStock option (right to buy) · Derivative	113,000	Not disclosed Strike: $9.74	Not disclosed	Disclosure SEC source: 0001548187-21-000027 · wf-form4_161860813440856.xml · derivative · entry 1 KLEMP WALTER V · CIK 0000938419 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,074,867 Underlying: Common Stock · 113,000 shares Expires 2031-01-21 F1 · date: The stock option was approved by the compensation committee of Soliton Inc.'s board of directors on January 21, 2021, subject to shareholder approval of the 2018 Stock Plan under which the option was granted. The shareholders of Soliton, Inc. approved the plan at the company's annual meeting on April 15, 2021. F3 · price: The options were issued in connection with the reporting person's Board of Director service to the Company F2 · derivative.exercise_date: The stock options set forth in this table vest in four equal annual installments and are subject to the grantee's continued service to the Company on each vesting date. Read SEC document
July 13, 2020 Filed Jul 14, 2020 22:03 UTC	Moleculin Biotech, Inc. MBRX · Entity 7886	Exercise / conversionRestricted Stock Units · Derivative	79,227	$0.00	$0.00	Disclosure SEC source: 0001659617-20-000178 · wf-form4_159476421761509.xml · derivative · entry 3 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,430,891 Underlying: Common Stock · 79,227 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On July 11, 2019, the reporting person was granted 316,907 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F3 · derivative.expiration_date: On July 11, 2019, the reporting person was granted 316,907 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document
July 13, 2020 Filed Jul 14, 2020 22:03 UTC	Moleculin Biotech, Inc. MBRX · Entity 7886	Tax withholdingCommon Stock	19,292	$0.86	$16,513.95	Disclosure SEC source: 0001659617-20-000178 · wf-form4_159476421761509.xml · nonDerivative · entry 2 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,027,659 F2 · shares: Shares withheld for payment of taxes upon vesting of restricted stock unit awards. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.